Samsung Biologics has published its formal offer prospectus to acquire PolyPeptide, deepening its push into peptide manufacturing as CDMOs race to expand capacity for GLP-1 and other peptide-based drugs.
PolyPeptide's specialized peptide expertise and global multi-site network to strengthen Samsung Biologics' multi-modality and global manufacturing excellence.
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
